JPM vs TBBK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
TBBK presents a conflicting profile characterized by a stable Piotroski F-Score of 4/9 and a valuation that sits between its defensive Graham Number ($42.46) and growth-based Intrinsic Value ($122.26). While the company boasts an exceptional ROE of 30.85% and an attractive forward P/E of 7.53, it has failed to beat earnings estimates in the last four consecutive quarters. Significant regulatory risks regarding capital adequacy and a bearish technical trend (0/100) temper the bullish valuation metrics. The stock currently functions as a value play with concerning short-term execution and regulatory headwinds.
Compare Another Pair
Related Comparisons
JPM vs TBBK: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and The Bancorp, Inc. (TBBK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.